{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:06:37Z","timestamp":1784261197828,"version":"3.55.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with relapsed or refractory (R\/R) mature natural killer cell and T-cell lymphoma have limited treatment options. To evaluate pralatrexate\u2019s performance and factors influencing its safety and efficacy in R\/R peripheral T-cell lymphoma (PTCL), we performed a pooled analysis of data from 4 similarly designed, regulatory-mandated prospective clinical trials. Of 221 patients (median age, 59 years; 67.0% male) in the study population, 48.9% had PTCL not otherwise specified (PTCL-NOS), 21.3% angioimmunoblastic T-cell lymphoma, and 11.8% ALK-negative anaplastic large cell lymphoma (ALCL). Patients received pralatrexate for a median of 2.56\u00a0months (range, 0.03-24.18) and had a 40.7% objective response rate with a median duration of response of 9.1\u00a0months, progression-free survival 4.6\u00a0months, and overall survival 16.3\u00a0months. The most common treatment-related all-grade adverse events were stomatitis, thrombocytopenia, white blood cell count decrease, pyrexia, and vomiting. Subgroup exploratory analyses suggest improved efficacy with 1 prior line of chemotherapy vs 2 or \u22654 prior lines; PTCL-NOS or ALCL vs transformed mycosis fungoides; chemotherapy and transplant before pralatrexate vs chemotherapy alone or chemotherapy with other nontransplant treatments. In conclusion, these pooled analysis results further support using pralatrexate in patients with R\/R PTCL. Prospective studies are needed to confirm the findings of subgroups analyses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010441","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T02:17:10Z","timestamp":1709345830000},"page":"2601-2611","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Pooled analysis of pralatrexate single-agent studies in patients with relapsed\/refractory peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"given":"Owen A.","family":"O\u2019Connor","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, University of Virginia Comprehensive Cancer Center, Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7579","authenticated-orcid":false,"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"3Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Wang","sequence":"additional","affiliation":[{"name":"4Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung-Chang Gang Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"5Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"},{"name":"6Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"7Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-5120","authenticated-orcid":false,"given":"Ee-Min","family":"Yeoh","sequence":"additional","affiliation":[{"name":"8Mundipharma Singapore Holdings Pte Ltd, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9325-0323","authenticated-orcid":false,"given":"Nick","family":"Manamley","sequence":"additional","affiliation":[{"name":"9Mundipharma Research Limited, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"5Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"20","key":"2024061015154998000_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024061015154998000_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3322\/caac.21589","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2024061015154998000_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/hematology.2019000012","article-title":"Emerging strategies in peripheral T-cell lymphoma","volume":"2019","author":"Mehta-Shah","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"2024061015154998000_bib4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Armitage","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024061015154998000_bib5","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024061015154998000_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"issue":"6","key":"2024061015154998000_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"2024061015154998000_bib8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.24992","article-title":"Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)","volume":"93","author":"Zhang","year":"2018","journal-title":"Am J Hematol"},{"key":"2024061015154998000_bib9","unstructured":"Food and Drug Administration, HHS\n          . Celgene Corporation and Teva Pharmaceutical Industries Ltd.; Withdrawal of Approval of Peripheral T-Cell Lymphoma Indication for ISTODAX (Romidepsin) for Injection and Romidepsin Injection. Accessed 26 January 2023. https:\/\/www.federalregister.gov\/d\/2022-09889."},{"issue":"8","key":"2024061015154998000_bib10","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"2024061015154998000_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/OTT.S93528","article-title":"Chidamide in the treatment of peripheral T-cell lymphoma","volume":"10","author":"Chan","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"3","key":"2024061015154998000_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"2024061015154998000_bib13","first-page":"1014","article-title":"Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy","volume":"52","author":"Yoshimitsu","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"2024061015154998000_bib14","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results","volume":"113","author":"Utsunomiya","year":"2022","journal-title":"Cancer Sci"},{"issue":"5","key":"2024061015154998000_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"2024061015154998000_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024061015154998000_bib17","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"issue":"11","key":"2024061015154998000_bib18","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024061015154998000_bib19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024061015154998000_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11523-019-00630-y","article-title":"Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study","volume":"14","author":"Hong","year":"2019","journal-title":"Target Oncol"},{"key":"2024061015154998000_bib21","author":"Wang","year":"15  2019"},{"issue":"10","key":"2024061015154998000_bib22","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma","volume":"108","author":"Maruyama","year":"2017","journal-title":"Cancer Sci"},{"issue":"suppl 1","key":"2024061015154998000_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/annonc\/11.suppl_1.S3","article-title":"Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms","volume":"11","author":"Harris","year":"2000","journal-title":"Ann Oncol"},{"key":"2024061015154998000_bib24","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","edition":"4th ed."},{"issue":"4","key":"2024061015154998000_bib25","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024061015154998000_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024061015154998000_bib27","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1080\/10428194.2020.1765232","article-title":"Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis","volume":"61","author":"Zhu","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2024061015154998000_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2024061015154998000_bib29","doi-asserted-by":"crossref","first-page":"pky038","DOI":"10.1093\/jncics\/pky038","article-title":"Strategy for assessing new drug value in orphan diseases: an international case match control analysis of the PROPEL study","volume":"2","author":"O'Connor","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"4","key":"2024061015154998000_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A\u00a0phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2601\/2228404\/blooda_adv-2023-010441-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2601\/2228404\/blooda_adv-2023-010441-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:16:18Z","timestamp":1718032578000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2601\/515169\/Pooled-analysis-of-pralatrexate-single-agent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010441","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}